The Theranos fiasco shows how much startup advisory boards matter


Image featuring silhouette of individuals at a board meeting in office
Image Credits: FangXiaNuo (opens in a new window) / Getty Images

Ariel Katz


Ariel Katz is the co-founder and CEO of H1.

More posts from Ariel Katz

The epic fall from grace of Elizabeth Holmes holds lessons for everybody from CEOs to investors, commercial partners, the media — social or otherwise — and the Silicon Valley hype machine that is always hungry for a new breakout star and unicorn company.

For pharmaceutical companies, especially medical affairs, the important lesson from this sad and sordid affair is as simple as it is powerful: Your advisory board matters — a lot.

Big names, little relevant expertise

Those five words characterize Theranos’ board. A quick look shows (former) politicians (George Shultz, William Perry, Sam Nunn, Henry Kissinger, Bill Frist), high-ranking members of the military (Gary Roughead, James Mattis) and corporate leaders without healthcare experience (Richard Kovacevich/banking and Riley Bechtel/engineering and construction).

Then there was the lone medical professional, the former director of the U.S. Centers for Disease Control and Prevention, William Foege — unless you want to count Bill Frist, an M.D. focused on cardiac transplants who switched to politics long before he joined Theranos’ board. Holmes herself was a college dropout at 19, and Theranos COO Sunny Balwani was an IT professional by training and experience.

Except for Foege, nobody knew the first thing about diagnostic testing, the technologies behind it, the challenges, the logistics, economics or even the biology. Mattis’ testimony in the Holmes trial makes this point clear.

“I thought all along that we were doing it on Theranos gear,” he told prosecutors, according to The Washington Post. He took the word of Holmes and the senior leadership team that the technology worked. Without any experience in the field, that’s probably pretty much all he could do.

What the board needed — and members should have insisted much earlier that this expertise needed to be added — was people capable of looking under the hood and scrutinizing every aspect of a system, that, if real, would make every other diagnostic testing system out there look like child’s play.

It was only in 2016 that Theranos added what Fortune magazine called a “startlingly well-qualified medical board.” Which it was. But by then, apparently, it was too late.

Lessons learned for advisory boards

The first lesson learned from this debacle is intuitive: While big names attract attention and lend credibility, you need domain expertise on your advisory boards from the start. Real boots-on-the-ground expertise from advisers who know what they’re talking about because they’ve lived it every day.

Advisory boards in (bio)pharmaceutical companies don’t normally feature secretaries of state or defense, but the risk associated with a board consisting only of high-level, international key opinion leaders can be similar: They are highly sought after, incredibly busy and might not be in a good position to dig into the data and details. They might keynote panels at the most prestigious conferences, know everybody who is anybody in the therapeutic area and publish in high Journal Impact Factor magazines, but do not see patients.

While advisory boards absolutely need these big names to inform strategic decisions, they also need members who can get into the weeds, help answer relevant, detailed medical questions and identify unmet medical needs of different patient populations. A highly functioning, diverse board needs to be in place to advise companies early on.

Once things have gone awry, even a “startlingly well-qualified” board might not be able to turn things around.

Job description: Rebel with a cause

Lesson No. 2 relates to the interesting case of the lone expert on the board: Foege was one of the most loyal Theranos supporters and the longest-tenured Theranos official (except Holmes) when the Theranos house of cards came tumbling down.

As this example shows, people, even experts, get sucked into the hype. That’s why it is good to have a “rebel” or two on your board, i.e., experts, often rising stars, who question convention, challenge the status quo, deeply vet the data and are not afraid to argue with the luminaries.

While it is easy to say, “Find yourself a couple of rebels driven by the cause of improving patient outcomes,” this is one of the more difficult advisory board positions to fill. Those who question established approaches might not be recommended by the experts they challenge. Therefore, the popular ways of building boards by asking established members for recommendations might prove ineffective or even counterproductive when it comes to these critical members.

This leaves medical affairs or commercial teams in life science companies with the tough job of finding these emerging experts with an independent streak using different approaches.

Scientific publications can be used as an early indicator of emerging experts. The number of publications, the impact factor of the journal and, importantly, the actual work they publish can help identify exceptional talent.

Social media is an emerging but increasingly important source of information. What healthcare providers communicate and whom they target, e.g., patients or colleagues, can help paint a more complete picture, especially of early-career professionals. Awards, active membership in medical societies, especially participation in guideline development committees and international collaborations are other factors companies consider.

Once found and onboarded, these emerging experts may turn out to be a pain in the neck, but if that means not going down the wrong path, that pain is well worth it.

The good, the bad, the ugly

The third lesson is an indirect one: A lot of time, energy, money and sleepless nights go into assembling an advisory board. Now use it for all that it’s worth.

Theranos never did this; they couldn’t, because their board was not meant to provide real oversight or ask hard questions. It was designed to help raise funds, inspire awe, squelch doubts and shut down criticism by the power of its members’ reputation. It did this very successfully — until it didn’t.

Criticism, while not pleasant, is vital, and therefore the goal must be to foster a culture of openness that encourages hard questions, deep vetting of data, fact-checking and constructive criticism.

The advisory board is just the place to have those open discussions among experts. As the Theranos example shows: If you fail to address challenges in the circle of trusted advisers, you might end up having to discuss them in public or — in this case — a court of law.

Your advisory board matters — a lot

Boards are critical to success, whether it is the success of an entire company or a specific drug development program. To live up to that expectation, boards of any description need diverse members who are highly qualified, engaged, collaborative and not afraid to ask uncomfortable questions and keep asking them.

The burden on boards in the life science industry is especially great because people’s health and lives are at stake. We might never know whether patients died as a direct result of Theranos’ misdiagnoses, but an “untold number of people were harmed by the erroneous results: Some underwent unnecessary procedures, received misdiagnoses of serious conditions and experienced emotional turmoil.”

The burden of vetting, questioning and fact-checking is on the board. The burden of building a board that is able to do so and takes that responsibility seriously — and enabling it by creating an environment of openness and trust and really listening to its input and feedback — is on the company.

Theranos starkly shows the possible consequences of failing to do so.

More TechCrunch

Microsoft announced on Tuesday during its annual Build conference that it’s bringing “Windows Volumetric Apps” to Meta Quest headsets. The partnership will allow Microsoft to bring Windows 365 and local…

Microsoft’s new ‘Volumetric Apps’ for Quest headsets extend Windows apps into the 3D space

The spam reached Bluesky by first crossing over two other decentralized networks: Mastodon and Nostr.

The ‘vote Trump’ spam that hit Bluesky in May came from decentralized rival Nostr

Welcome to TechCrunch Fintech! This week, we’re looking at the continued fallout from Synapse’s bankruptcy, how Layer wants to disrupt SMB accounting, and much more! To get a roundup of…

There’s a real appetite for a fintech alternative to QuickBooks

The company is hoping to produce electricity at $13 per megawatt hour, which would be more than 50% cheaper than traditional onshore wind.

Bill Gates-backed wind startup AirLoom is raising $12M, filings reveal

Generative AI makes stuff up. It can be biased. Sometimes it spits out toxic text. So can it be “safe”? Rick Caccia, the CEO of WitnessAI, believes it can. “Securing…

WitnessAI is building guardrails for generative AI models

It’s not often that you hear about a seed round above $10 million. H, a startup based in Paris and previously known as Holistic AI, has announced a $220 million…

French AI startup H raises $220M seed round

Hey there, Series A to B startups with $35 million or less in funding — we’ve got an exciting opportunity that’s tailor-made for your growth journey! If you’re looking to…

Boost your startup’s growth with a ScaleUp package at TC Disrupt 2024

TikTok is pulling out all the stops to prevent its impending ban in the United States. Aside from initiating legal action against the U.S. government, that means shaping up its…

As a US ban looms, TikTok announces a $1M program for socially driven creators

Microsoft wants to put its Copilot everywhere. It’s only a matter of time before Microsoft renames its annual Build developer conference to Microsoft Copilot. Hopefully, some of those upcoming events…

Microsoft’s Power Automate no-code platform adds AI flows

Build is Microsoft’s largest developer conference and of course, it’s all about AI this year. So it’s no surprise that GitHub’s Copilot, GitHub’s “AI pair programming tool,” is taking center…

GitHub Copilot gets extensions

Microsoft wants to make its brand of generative AI more useful for teams — specifically teams across corporations and large enterprise organizations. This morning at its annual Build dev conference,…

Microsoft intros a Copilot for teams

Microsoft’s big focus at this year’s Build conference is generative AI. And to that end, the tech giant announced a series of updates to its platforms for building generative AI-powered…

Microsoft upgrades its AI app-building platforms

The U.K.’s data protection watchdog has closed an almost year-long investigation of Snap’s AI chatbot, My AI — saying it’s satisfied the social media firm has addressed concerns about risks…

UK data protection watchdog ends privacy probe of Snap’s GenAI chatbot, but warns industry

U.S. cell carrier Patriot Mobile experienced a data breach that included subscribers’ personal information, including full names, email addresses, home ZIP codes and account PINs, TechCrunch has learned. Patriot Mobile,…

Conservative cell carrier Patriot Mobile hit by data breach

It’s been three years since Spotify acquired live audio startup Betty Labs, and yet the music streaming service isn’t leveraging the technology to its fullest potential — at least not…

Spotify’s ‘Listening Party’ feature falls short of expectations

Alchemist Accelerator has a new pile of AI-forward companies demoing their wares today, if you care to watch, and the program itself is making some international moves into Tokyo and…

Alchemist’s latest batch puts AI to work as accelerator expands to Tokyo, Doha

“Late Pledge” allows campaign creators to continue collecting money even after the campaign has closed.

Kickstarter now lets you pledge after a campaign closes

Stack AI’s co-founders, Antoni Rosinol and Bernardo Aceituno, were PhD students at MIT wrapping up their degrees in 2022 just as large language models were becoming more mainstream. ChatGPT would…

Stack AI wants to make it easier to build AI-fueled workflows

Pinecone, the vector database startup founded by Edo Liberty, the former head of Amazon’s AI Labs, has long been at the forefront of helping businesses augment large language models (LLMs)…

Pinecone launches its serverless vector database out of preview

Young geothermal energy wells can be like budding prodigies, each brimming with potential to outshine their peers. But like people, most decline with age. In California, for example, the amount…

Special mud helps XGS Energy get more power out of geothermal wells

Featured Article

Sonos finally made some headphones

The market play is clear from the outset: The $449 headphones are firmly targeted at an audience that would otherwise be purchasing the Bose QC Ultra or Apple AirPods Max.

7 hours ago
Sonos finally made some headphones

Adobe says the feature is up to the task, regardless of how complex of a background the object is set against.

Adobe brings Firefly AI-powered Generative Remove to Lightroom

All cars suffer when the mercury drops, but electric vehicles suffer more than most as heaters draw more power and batteries charge more slowly as the liquid electrolyte inside thickens.…

Porsche Ventures invests in battery startup South 8 to boost cold-weather EV performance

Scale AI has raised a $1 billion Series F round from a slew of big-name institutional and corporate investors including Amazon and Meta.

Data-labeling startup Scale AI raises $1B as valuation doubles to $13.8B

The new coalition, Tech Against Scams, will work together to find ways to fight back against the tools used by scammers and to better educate the public against financial scams.

Meta, Match, Coinbase and others team up to fight online fraud and crypto scams

It’s a wrap: European Union lawmakers have given the final approval to set up the bloc’s flagship, risk-based regulations for artificial intelligence.

EU Council gives final nod to set up risk-based regulations for AI

London-based fintech Vitesse has closed a $93 million Series C round of funding led by investment giant KKR.

Vitesse, a payments and treasury management platform for insurers, raises $93M to fuel US expansion

Zen Educate, an online marketplace that connects schools with teachers, has raised $37 million in a Series B round of funding. The raise comes amid a growing teacher shortage crisis…

Zen Educate raises $37M and acquires Aquinas Education as it tries to address the teacher shortage

“When I heard the released demo, I was shocked, angered and in disbelief that Mr. Altman would pursue a voice that sounded so eerily similar to mine.”

Scarlett Johansson says that OpenAI approached her to use her voice

A new self-driving truck — manufactured by Volvo and loaded with autonomous vehicle tech developed by Aurora Innovation — could be on public highways as early as this summer.  The…

Aurora and Volvo unveil self-driving truck designed for a driverless future